Natural product therapy for Diabetes mellitus: Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/White Spruce, among others, increases islet insulin levels, islet cell mass and glucose tolerance via down-regulation of NMDA receptor GluN2A, 30/October/2016, 6.02 pm

Introduction:  A study from the Institute of Metabolic Physiology, Heinrich Heine University, Düsseldorf, Germany shows that: “Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment.” This study was published in the 16 March 2015  issue of the Journal “Nature Medicine” (one of the best journal in “General Medicine” with an impact factor of 30+ ) by Prof. Lammert E, Marquard […]

Vitamin-based Lifespan extension therapy: α-Tocopherol (Vitamin-E) increases life span via up-regulation of its target gene BubR1, 30/October/2016, 1.08 pm

 What they say: Introduction:  A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published in the 1 July  2014 issue of the journal  “EMBO” by Prof […]

Natural product therapy for triple-negative breast tumors: Baicalein (5,6,7-trihydroxyflavone), a flavone isolated from the roots of Scutellaria baicalensis/lateriflora and Oroxylum indicum, increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 30/October/2015, 12. 02 pm

Introduction: What they say A study from the Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA shows that “PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression“ Another study, carried out in parallel, from the Breast Cancer Now Research Unit, Division […]

Molecular therapy for Myocardial Infarction: MiRNA-24 improves myocardial function after myocardial infarction via up-regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 29/October/2016, 8.32 pm

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others. On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction:  MiRNA-24 improves myocardial function after myocardial infarction via  up-regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase […]

Molecular therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: BMP2 promotes an insulin-sensitized state via up-regulation of reprogramming protein Lin28, 29/October/2016, 11.11 am

Introduction: A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study was published in the 30 September  2011 issue of the Journal “Cell” [One of the best journals in Biological sciences with an I.F of 28.71]  by Prof Daley GQ, […]

Small molecule-based PD-1 pathway blockade for Human cancer therapy: DEAR1/TRIM62 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 29/october/2016, 11. 30 am

Introduction:What they say: A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.” This study was published in the 28 September 2016 issue of Cancer Discovery (one of the best journals in Cancer […]